Current Ovarian Cancer Maintenance Strategies and Promising New Developments

Gogineni, Vinaya; Morand, Susan; Staats, Hannah; Royfman, Rachel; Devanaboyina, Monika; Einloth, Katelyn; Dever, Danielle; Stanbery, Laura; Aaron, Phylicia; Manning, Luisa; Walter, Adam; Edelman, Gerald M.; Dworkin, Lance D.; Nemunaitis, John

doi:10.7150/jca.49406

Cited by 42 publications

(38 citation statements)

References 138 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard of care for newly diagnosed advanced ovarian cancer (Stage IIIb-IV) involves either primary debulking surgery followed by adjuvant chemotherapy with paclitaxel and carboplatin or neoadjuvant chemotherapy with interval debulking surgery followed by adjuvant chemotherapy [1,2]. Although the majority of patients achieve complete remission with either approach, 60-75% still relapse within 2-3 years with no significant difference in OS between the treatment options.…”

Section: Introductionmentioning

confidence: 99%

“…Although the majority of patients achieve complete remission with either approach, 60-75% still relapse within 2-3 years with no significant difference in OS between the treatment options. Within the past few years, maintenance therapy has demonstrated benefits with optimal frontline maintenance including bevacizumab, niraparib or olaparib/bevacizumab combination [2][3][4], but most durable clinical response are seen in patients with either BRCA germline or somatic mutations [5,6] as well as HRD molecular profiles [3]. HRP patients demonstrate no to minimal benefit with PARPi therapy [3,7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer

Walter¹,

Rocconi

Monk

et al. 2021

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer

Walter¹,

Rocconi

Monk

et al. 2021

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is the most lethal gynecological malignancy due to its late diagnosis and high recurrence [ 74 ], showing a low five-year survival rate of around 45% [ 75 ]. Currently, the first-line treatment consists of surgery and chemotherapy (mainly based on platinum compounds).…”

Section: Adcs For Ovarian Cancermentioning

confidence: 99%

Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives

2021

View full text Add to dashboard Cite

In the last decade, antibody-drug conjugates (ADCs), normally formed by a humanized antibody and a small drug via a chemical cleavable or non-cleavable linker, have emerged as a potential treatment strategy in cancer disease. They allow to get a selective delivery of the chemotherapeutic agents at the tumor level, and, consequently, to improve the antitumor efficacy and, especially to decrease chemotherapy-related toxicity. Currently, nine antibody-drug conjugate-based formulations have been already approved and more than 80 are under clinical trials for the treatment of several tumors, especially breast cancer, lymphomas, and multiple myeloma. To date, no ADCs have been approved for the treatment of gynecological formulations, but many formulations have been developed and have reached the clinical stage, especially for the treatment of ovarian cancer, an aggressive disease with a low five-year survival rate. This manuscript analyzes the ADCs formulations that are under clinical research in the treatment of gynecological carcinomas, specifically ovarian, endometrial, and cervical tumors.

show abstract

“…Because the clinical manifestations of early OC are hidden or unspecific, OC is often called a silent killer, and approximately 70 % of them are diagnosed with an advanced stage [ 4 ]. As reported, the 5-year survival rate for FIGO stage I is 90 %, stage II is 65 %, stage III is 34 %, and stage IV is 15 % [ 5 , 6 ]. However, current improvements in treatment methods could only slightly improve OC survival rates [ 7 ].…”

Section: Introductionmentioning

confidence: 96%

CACNA1C is a prognostic predictor for patients with ovarian cancer

Chang

Dong

2021

J Ovarian Res

View full text Add to dashboard Cite

Background CACNA1C, as a type of voltage-dependent calcium ion transmembrane channel, played regulatory roles in the development and progress of multiple tumors. This study was aimed to analyze the roles of CACNA1C in ovarian cancer (OC) of overall survival (OS) and to explore its relationships with immunity. Methods Single gene mRNA sequencing data and corresponding clinical information were obtained from The Cancer Genome Atlas Database (TCGA) and the International Cancer Genome Consortium (ICGC) datasets. Gene set enrichment analysis (GSEA) was used to identify CACNA1C-related signal pathways. Univariate and multivariate Cox regression analyses were applied to evaluate independent prognostic factors. Besides, associations between CACNA1C and immunity were also explored. Results CACNA1C had a lower expression in OC tumor tissues than in normal tissues (P < 0.001), with significant OS (P = 0.013) and a low diagnostic efficiency. We further validated the expression levels of CACNA1C in OC by means of the ICGC dataset (P = 0.01), qRT-PCR results (P < 0.001) and the HPA database. Univariate and multivariate Cox hazard regression analyses indicated that CACNA1C could be an independent risk factor of OS for OC patients (both P < 0.001). Five significant CACNA1C-related signaling pathways were identified by means of GSEA. As for genetic alteration analysis, altered CACNA1C groups were significantly associated with OS (P = 0.0169), progression-free survival (P = 0.0404), disease-free survival (P = 0.0417) and disease-specific survival (P = 9.280e-3), compared with unaltered groups in OC. Besides, CACNA1C was dramatically associated with microsatellite instability (MSI) and immunity. Conclusions Our results shed light on that CACNA1C could be a prognostic predictor of OS in OC and it was closely related to immunity.

show abstract

Current Ovarian Cancer Maintenance Strategies and Promising New Developments

Cited by 42 publications

References 138 publications

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer

Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives

CACNA1C is a prognostic predictor for patients with ovarian cancer

Contact Info

Product

Resources

About